Developing new treatments for breast cancer resistant to current therapies
Official title: Irreversible Estrogen Receptor Inhibitors
Funded at Xavier University of Louisiana · NIH-10875653 · Data updated 2026-11-12
This study is working on new treatments for patients with metastatic estrogen receptor-positive breast cancer who haven't had success with current therapies, by developing special drugs that can permanently block the estrogen receptor to help stop cancer growth.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Xavier University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | August 16, 2022 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $187,500 |
| NIH project number | 5R16GM147662-03 |
| Project ID | NIH-10875653 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with metastatic ER+ breast cancer who have experienced resistance to standard endocrine therapies.
✕Less likely to help
Patients with non-ER+ breast cancer or those who have not yet undergone endocrine therapy may not benefit from this research.
What this research studies
This research focuses on creating irreversible estrogen receptor inhibitors to treat patients with metastatic estrogen receptor-positive (ER+) breast cancer who have not responded to existing therapies. The approach involves designing and synthesizing new compounds that can bind to the estrogen receptor and form a permanent bond, potentially overcoming resistance mechanisms. By targeting specific mutations in the estrogen receptor, the research aims to provide new therapeutic options for patients facing treatment failure. The study will evaluate the effectiveness of these inhibitors in reducing cancer cell proliferation.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with metastatic ER+ breast cancer who currently have limited alternatives.
How similar studies have gone: Previous research has shown promise in developing irreversible estrogen receptor antagonists, indicating potential for success in this novel approach.
Where this research is happening
-
Xavier University of Louisiana
New Orleans, United States Active
Researchers
- Principal investigator: Payton-Stewart, Florastina L — Xavier University of Louisiana
- Study coordinator: Payton-Stewart, Florastina L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.